| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A systematic review of modifiable risk factors in the progression of multiple sclerosis
|
Hempel, Susanne
|
|
2017
|
23 |
4 |
p. 525-533
|
artikel
|
| 2 |
A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis
|
Hempel, Susanne
|
|
2017
|
23 |
4 |
p. 513-524
|
artikel
|
| 3 |
Biotin supplementation in MS clinically valuable but can alter multiple blood test results
|
Siddiqui, Ursela
|
|
2017
|
23 |
4 |
p. 619-620
|
artikel
|
| 4 |
Comment on extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
|
Gaitán, María Inés
|
|
2017
|
23 |
4 |
p. 617-618
|
artikel
|
| 5 |
Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features
|
Sbardella, Emilia
|
|
2017
|
23 |
4 |
p. 546-555
|
artikel
|
| 6 |
Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study
|
McKay, Kyla A
|
|
2017
|
23 |
4 |
p. 588-596
|
artikel
|
| 7 |
Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
|
Boudot de la Motte, Marine
|
|
2017
|
23 |
4 |
p. 614-616
|
artikel
|
| 8 |
Grey matter atrophy is associated with disability increase in natalizumab-treated patients
|
Ciampi, Ethel
|
|
2017
|
23 |
4 |
p. 556-566
|
artikel
|
| 9 |
Imaging of microglial activation in MS using PET: Research use and potential future clinical application
|
Airas, Laura
|
|
2017
|
23 |
4 |
p. 496-504
|
artikel
|
| 10 |
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS – Commentary
|
Ontaneda, Daniel
|
|
2017
|
23 |
4 |
p. 508-509
|
artikel
|
| 11 |
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS – NO
|
Fox, Robert J
|
|
2017
|
23 |
4 |
p. 506-508
|
artikel
|
| 12 |
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS – YES
|
Chataway, Jeremy
|
|
2017
|
23 |
4 |
p. 505-506
|
artikel
|
| 13 |
Indirect comparisons of treatment effects: Network meta-analyses
|
Sormani, Maria Pia
|
|
2017
|
23 |
4 |
p. 510-512
|
artikel
|
| 14 |
Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
|
Vermersch, Patrick
|
|
2017
|
23 |
4 |
p. 604-613
|
artikel
|
| 15 |
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study
|
D’Souza, Marcus
|
|
2017
|
23 |
4 |
p. 597-603
|
artikel
|
| 16 |
Reply to Letter to the Editor: Biotin supplementation in MS clinically valuable but can alter multiple blood test results by Siddiqui U, et al.
|
Tourbah, Ayman
|
|
2017
|
23 |
4 |
p. 620-621
|
artikel
|
| 17 |
Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment
|
Bühler, Ulrike
|
|
2017
|
23 |
4 |
p. 567-576
|
artikel
|
| 18 |
Trajectory of MS disease course for men and women over three eras
|
Hum, Stanley
|
|
2017
|
23 |
4 |
p. 534-545
|
artikel
|
| 19 |
When are we going to take modifiable risk factors more seriously in multiple sclerosis?
|
Coetzee, Tim
|
|
2017
|
23 |
4 |
p. 494-495
|
artikel
|
| 20 |
Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation
|
Vacchi, Laura
|
|
2017
|
23 |
4 |
p. 577-587
|
artikel
|
Tijdschrift beschrijving